教师基本信息：
姓名：王陈继
职称：研究员
电子邮箱：chenjiwang@fudan.edu.cn
办公地点：生命科学楼C517室
研究方向：
1. 研究高频突变基因（特别是泛素-蛋白酶体途径相关基因）在恶性肿瘤中的作用机制，阐明其致癌机理，并探索其成为肿瘤 “精准治疗”分型依据和药物靶标的可能性；
2. 研究泛素-蛋白酶体、自噬体、溶酶体、线粒体、囊泡运输和细胞器互作等相关途径基因突变导致人类神经/代谢性遗传病、神经退行性疾病的分子机制及靶向治疗的策略。
个人简介：
研究员，博士生导师。2004年毕业于四川大学理科创新班，获理学学士学位；2010年毕业于复旦大学生命科学学院，获理学博士学位。2010年任助理研究员，2016年任青年副研究员，2017年任副研究员，2025年任研究员。近年来承担国家自然基金六项，重点研发计划子课题二项及校级课题二项。作为通讯作者在《Nature Medicine》、《Nature Communications》、《Science Advances》和《Cell Death& Differentiation》等学术期刊发表SCI论文40余篇。
授课情况：
承担本科生课程《细胞生物学》、《细胞生物学导论》的教学工作。
招生专业：
遗传学
科研项目：
1. 国家自然科学基金重大研究计划集成项目，糖脂代谢重编程驱动肿瘤细胞周期进程的作用与机制，2024.1-2026.12，
2. 国家自然科学基金面上项目，TBCK突变引起RAB5依赖性囊泡运输缺陷导致神经发育障碍的机制研究, 2024.01 - 2027.12
3. 上海市母胎医学重点实验室开放课题，胎盘特异表达基因XAGE2参与孕酮合成代谢调控的分子机制, 2023.1-2024.12
4. 国家重点研发计划项目,特定环境条件下干细胞对心血管功能的重塑, 2023.1-2027.3
5. 上海市自然科学基金面上项目, KCTD7基因突变导致神经元蜡样脂褐质沉积症的分子机制, 2022.4-2025.3
6. 国家自然科学基金面上项目，延胡索酸水合酶基因突变激活Keap1-mTORC2-AKT信号通路促肾癌的分子机制及靶向治疗策略，2020.1- 2023.12
代表性论文和论著：
1. Zhang W, Feng T, Wang Y, Cai T, Wang W, Zhu S, Chen Y, Zhang H, Ye D*,Chang K*, andWang C*.DPP9 Inhibition Enhances Antitumor Immunity Through Suppression of BRISC Complex-Mediated PD-L1 Expression. Cell Death Differ. 2026 Mar 14. doi: 10.1038/s41418-026-01704-x.
2. Chen Y, Xu X, Wang H, Wang C*. The TBCK-PPP1R21-FERRY3/C12orf4 Complex: A RAB5-GAP Brake Essential for Endo-Lysosomal Homeostasis. Autophagy. 2026 May;22(5):1142-1144.
3. Fei S, XU X, Wang T, Jiang X, Chen Y, Yuan R, Lv Z, Gao Z, Liu H, Chen X, Wang C*, Gao K*. FBXW7 Mutations Reprogram Glucose Metabolism by Activating the ETV6-GLUT1 Axis. Mol Cancer. 2026 Feb 14;25(1):79.
4. Wang Y, Xu X, Cao X, He H, Qin Y, Deng T, Zhang Z, Wu L, Wang C*, Wang H. TBCK Syndrome Pathogenesis: A TBCK-PPP1R21-C12orf4 Complex Regulating RAB5-dependent Endo-lysosomal Homeostasis.Sci Bull. 2025 Oct 25:S2095-9273.
5. Jiao D, Chang K, Chen Y, Jin J, Mo R, Zhang Y, Xu Y*, Wang L*, Wang C*.Disruption of WSB2-mediated NOXA degradation induces synthetic lethality to Anti-apoptotic BCL-2 Family protein inhibitors. eLife. 2025 Jul 23;13:RP98372.
6. Wang Z, Li L, Ye Q, Lei Y, Lu M, Ye L, Kang J, Huang W, Xu S, Wang K, Liu J, Gao Y, Wang C*, Ma J*, Li L*. Cancer-associated SPOP mutations enlarge nuclear size and facilitate nuclear envelope rupture upon farnesyltransferase inhibitor treatment.J Clin Invest. 2025 Jul 15;135(14):e189048.
7. Shi Q, Liu Y, Yang W, Mo R, Li Y, Wang C*, Gao K*. The Covalent Modification of STAT1 Cysteines by Sulforaphane Promotes Antitumor Immunity via Blocking IFN-γ-induced PD-L1 expression. Redox Biology. 2025 Feb 11;81:103543.
8. He J, Ye L, Xu H, Yang H, Shen J, Li M, Weng S, Jiao D, Chu C, Liao Q, Zhou H, Zhu J, Wang C*, Xu X*. Exome Sequencing Identifies Low-Frequency Mutation of NFE2L3 Conferring Risk for Myopic Maculopathy.Natl Sci Rev.2024 Aug 29;12(2):nwae291.
9. Gao K*, Jia F, Li Y*, Wang C*. DDHD2 promotes lipid droplet catabolism by acting as a tag lipase and a cargo receptor for lipophagy. Autophagy. 2024 Oct;20(10):2346-2348.
11. Gao K*, Xu X, Wang C*. Excessive mitophagy drives FBXL4 mutation-caused mitochondrial DNA depletion syndrome. Trends Mol Med. 2023 Dec 19:S1471-4914(23)00279-4.
12. Gao K*, Chen Y, Wang C*.Excessive BNIP3- and BNIP3L-dependent mitophagy underlies the pathogenesis of FBXL4-mutated mitochondrial DNA depletion syndrome.Autophagy. 2023 Oct 24:1-3.
13. Chen Y, Jiao D, He H, Sun H, Liu Y, Shi Q, Zhang P, Li Y, Mo R*, Gao K*, Wang C*.Disruption of the Keap1-mTORC2 axis by Cancer-derived Keap1/mLST8 Mutations Leads to Oncogenic mTORC2-AKT Activation. Redox Bio. 2023 Sep 5;67:102872.
14. Chang K, Chen Y, Zhang X, Zhang W, Xu T, Zeng B, Dai B*, Xu F*, Ye D*, Wang C*.DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma. Cancer Res. 2023 Dec 1;83(23):3940-3955.
15. Chen Y, Jiao D, Liu Y, Xu X, Wang Y, Hexige S, Gao K, Chen Y*, Zhao S*, Ma L*, Wang C*. FBXL4 Mutations Cause Excessive Mitophagy via BNIP3/BNIP3L Accumulation Leading to Mitochondrial DNA Depletion Syndrome. Cell Death Differ. 2023 Oct;30(10):2351-2363.
16. Wang Y, Wang H*, Wang C*. Lysosomal dysfunction, autophagic defects, and CLN5 accumulation underlie the pathogenesis of KCTD7-mutated neuronal ceroid lipofuscinoses. Autophagy. 2023 Jun;19(6):1876-1878.
17. Gao K*, Shi Q, Gu Y, Yang W, He Y, Lv Z, Ding Y, Cao W, Wang C*, Wan X*.SPOP Mutations Promote Tumor Immune Escape in Endometrial Cancer via the IRF1–PD-L1 Axis. Cell Death Differ. 2023 Feb;30(2):475-487.
18. Wang Y, Cao X, Liu P, Zeng W, Peng R, Shi Q, Feng K, Zhang P, Sun H, Wang C*, Wang H*. KCTD7 mutations impair the trafficking of lysosomal enzymes through CLN5 accumulation to cause neuronal ceroid lipofuscinoses. Sci Adv. 2022 Aug 5;8(31):eabm5578.
19. Gao K*, Shi Q, Liu Y,Wang C*. Enhanced autophagy and NFE2L2/NRF2 pathway activation in SPOP mutation-driven prostate cancer. Autophagy. 2022 Aug;18(8):2013-2015.
20. Shi Q, Jin X, Zhang P, Li Q, He H, Zhao X, Lv Z, Zhao S, Li Y, Gao K*,Wang C*. SPOP Mutations Promote p62/SQSTM1-dependent Autophagy and Nrf2 Activation in Prostate Cancer. Cell Death Differ. 2022 Jun;29(6):1228-1239.
21. Zhang P*, Gao K*, Zhang L, Sun H, Zhao X, Liu Y, Lv Z, Shi Q, Chen Y, Jiao D, Li Y, Gu W*, Wang C*.CRL2-KLHDC3 E3 ubiquitin ligase complex suppresses ferroptosis through promoting p14ARF degradation. Cell Death Differ. 2022 Apr;29(4):758-771.
22. Zhang J, Gao K, Xie H, Wang D, Zhang P, Wei T, Yan Y, Pan Y, Chen H, Shi Q, Yao Li Y, Zhao S, Hou X, Weroha SJ, Wang Y, Zhang J, Karnes RJ, Wang L, Wang C*, Huang H*. SPOP mutation induces DNA methylation via stabilizing GLP/G9a. Nat Comm. 2021 Sep 29;12(1):5716.
23. Ma J, Shi Q, Cui G, Sheng H, Botuyan MV, Zhou Y, Yan Y, He Y, Wang L, Wang Y, Georges Mer*, Ye D*, Wang C*, Huang H*. SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition. Nat Comm. 2021 Oct 1;12(1):5779.
24. Jin X*, Qing S, Li Q, Zhuang H, Shen L, Li J, Qi H, Lin T, Lin Z, Wang J, Cao X, Yang J, Ma Q, Cong L, Xi Y, Fang S, Meng X, Gong Z, Ye M, Wang S*, Wang C*, Gao K*. Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis.Nucleic Acids Res. 2021 Jul 9;49(12):6788-6803.
25. Jin X, Shi Q, Li Q, Zhou L, Wang J, Jiang L, Zhao X, Feng K, Lin T, Lin Z, Zhuang H, Yang J, Hu C, Zhang L, Shen L, Lu Y, Zhu J, Wang H, Qi H, Meng X, Xi Y, Pan J, Fang S, Tian H, Zhou C, Zhang P, Gao K, Zhao S, Li Y, Gong Z, Wang C*.CRL3-SPOP Ubiquitin Ligase Complex Suppresses the Growth of Diffuse Large B-cell Lymphoma by Negatively Regulating the MyD88/NF-κB Signaling. Leukemia. 2020 May;34(5):1305-1314.
26. Ma J, Peng J, Chang K, Shi Q, Gan H, Gao K, Feng K, Xu F,Zhang H, Dai B, Zhu Y, Shi G, Shen Y, Zhu Y, Qin X, Li Y, Zhang P, Ye D*, Wang C*. SPOP Promotes ATF2 Ubiquitination and Degradation to Suppress Prostate Cancer Progression. J Exp Clin Canc Res. 2018 Jul 11;37(1):145.
27. Zhang P, Wang D, Ren S, Zhao Y, Gao K, Ye Z, Wang S, Lin D, Pang X, Pan C, Zhu Y, Yan Y, Wu D, He Y, Zhang J, Lu D, Liu X, Yu L, Zhao S, Li Y, Wang L, Wang Y, Chen Y, Sun Y*, Wang C*, Huang H*. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med. 2017 Sep;23(9):1055-1062.